ASX
LCT 0.097    Last updated 10.11 am
Fact sheet
The following fact sheets provide a summary of our current business and research pipeline.
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.

Fact sheet

The following fact sheet provides a summary of our current business and research pipeline.

Cell therapy for neurodegenerative diseases

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercialising regenerative treatments which restore function using naturally occurring cells.

 

Our lead product, NTCELL®, is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation NTCELL functions as a biological factory, producing factors to promote new central nervous system growth and repair disease-induced nerve degeneration.

 

A Phase IIb trial of NTCELL for Parkinson's disease is currently underway. It aims to confirm the most effective dose of NTCELL, define any placebo component of the response and further identify the initial target Parkinson’s disease patient sub group. If the trial is successful LCT will apply for provisional consent to treat paying patients in New Zealand and launch NTCELL as the first disease modifying treatment for Parkinson’s disease, in 2017.

 

In addition to Parkinson’s disease, NTCELL has the potential to be used in a number of other central nervous system indications, including Huntington’s, Alzheimer’s and motor neurone diseases including amyotrophic lateral sclerosis (ALS).

 

LCT’s proprietary encapsulation technology, IMMUPEL™, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system.

 

LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges and is incorporated in Australia, with operations based in New Zealand.

— 20 January 2017

Appendix 4C Quarterly Cash Flow Report 31 December 2016

Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 December 2016. The Appendix 4C is attached. The company ended the quarter with a cash balance of $8,623,788 compared to $4,436,282 in the previous quarter. The increase is primarily due to the private placement partially offset by operating payments.

Read More Read Less

— 11 January 2017

US choroid plexus cells patent application published

Living Cell Technologies Limited has just received notice from the United States Patent and Trademark Office that its patent application “TREATMENT OF CNS DISEASE WITH INDUCIBLE CHOROID PLEXUS CELLS” No.15/154,709 was published with a date of 15 December 2016. The application was filed on 13 May 2016 and the provisional application No. 62/162,390 was filed on 15 May 2015.

Read More Read Less
Load More

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
— 16 November 2016

LCT Annual General Meeting. To be held at Sheraton on the Park, 161 Elizabeth Street, Sydney at 10.30am.

Load More
Announcements

— 20 January 2017

Appendix 4C Quarterly Cash Flow Report 31 December 2016

Living Cell Technologies Limited today released its cash flow report for the quarter ended 31 December 2016. The Appendix 4C is attached. The company ended the quarter with a cash balance of $8,623,788 compared to $4,436,282 in the previous quarter. The increase is primarily due to the private placement partially offset by operating payments.

Read More Read Less

— 11 January 2017

US choroid plexus cells patent application published

Living Cell Technologies Limited has just received notice from the United States Patent and Trademark Office that its patent application “TREATMENT OF CNS DISEASE WITH INDUCIBLE CHOROID PLEXUS CELLS” No.15/154,709 was published with a date of 15 December 2016. The application was filed on 13 May 2016 and the provisional application No. 62/162,390 was filed on 15 May 2015.

Read More Read Less
Load More
LCT in the News

— 1 March 2016

LCT expects crucial Parkinson’s clinical trial results in early 2017

Australasian biotech company Living Cell Technologies says it will know the outcome of a make-or-break clinical trial on its regenerative cell therapy for Parkinson's disease in the first quarter of next year. If the trial succeeds, Living Cell's lead product NTCELL will be the world's first disease-modifying treatment for Parkinson's as existing treatments only deal with the symptoms rather than stopping the degeneration of the brain.

Read More Read Less
Load More
Events
— 16 November 2016

LCT Annual General Meeting. To be held at Sheraton on the Park, 161 Elizabeth Street, Sydney at 10.30am.

Load More
Register for email updates
Register now to receive our newsletter and updates on LCT’s activities and progress.